jcm-logo

Journal Browser

Journal Browser

New Sights in Retinal Diseases Therapeutics: Innovation and Clinical Practice

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 20 October 2026 | Viewed by 777

Special Issue Editors


E-Mail Website
Guest Editor
Department of Translational Biomedicine Neuroscience, University of Bari “Aldo Moro”, 70121 Bari, Italy
Interests: retinal diseases; central serous chorioretinopathy; age-related macular degeneration; eye diseases; diabetic retinopathy

E-Mail Website
Guest Editor
Department of Translational Biomedicine Neuroscience, University of Bari “Aldo Moro”, 70125 Bari, Italy
Interests: retinal diseases; central serous chorioretinopathy; age-related macular degeneration; eye diseases; diabetic retinopathy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Medicine, Surgery and Pharmacy, University of Sassari, Viale San Pietro 43, 07100 Sassari, Italy
Interests: retinal diseases; central serous chorioretinopathy; age-related macular degeneration; eye diseases; diabetic retinopathy

E-Mail Website
Guest Editor
Ophthalmol Unit, Fdn Policlin University A Gemelli IRCCS, Rome, Italy
Interests: retinal diseases; central serous chorioretinopathy; age-related macular degeneration; eye diseases; diabetic retinopathy

Special Issue Information

Dear Colleagues,

On behalf of the Journal of Clinical Medicine Editorial Team, we are pleased to introduce a Special Issue entitled “New Sights in Retinal Diseases Therapeutics: Innovation and Clinical Practice.”

Over the past decade, the field of retinal disease management has undergone a profound transformation. This evolution has been driven by significant progress in both retinal imaging technologies and therapeutic strategies. Multimodal imaging now offers an increasingly precise evaluation of retinal pathologies and enables the identification of novel biomarkers that can guide treatment decisions and predict therapeutic outcomes.

This Special Issue is dedicated to showcasing recent advancements in the diagnosis and treatment of retinal diseases, and to exploring how these innovations are reshaping clinical practice. We welcome a wide range of contributions, spanning from cutting-edge diagnostic techniques to emerging therapies for retinal disorders.

We invite the submission of high-quality original research articles as well as insightful reviews that reflect the current state of knowledge and future directions in the field.

Dr. Giacomo Boscia
Dr. Pasquale Viggiano
Dr. Stefano Dore
Prof. Dr. Alfonso Savastano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • retinal diseases
  • central serous chorioretinopathy
  • age-related macular degeneration
  • eye diseases
  • diabetic retinopathy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 459 KB  
Article
Real-World Outcomes and Choroidal Vascular Structural Changes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration
by Lidia Remolí-Sargues, Clara Monferrer-Adsuara, Verónica Castro-Navarro, Belén López-Salvador, Ester Francés-Muñoz, Emma Marín-Payá, Juan Marín-Montiel and Enrique López-Sánchez
J. Clin. Med. 2026, 15(5), 2031; https://doi.org/10.3390/jcm15052031 - 6 Mar 2026
Viewed by 520
Abstract
Objectives: The objective of this study was to investigate choroidal structural alterations and evaluate the outcomes of switching to faricimab in patients with neovascular age-related macular degeneration (nAMD) previously treated with other anti-vascular endothelial growth factor (anti-VEGF) therapies after 12 months of follow-up. [...] Read more.
Objectives: The objective of this study was to investigate choroidal structural alterations and evaluate the outcomes of switching to faricimab in patients with neovascular age-related macular degeneration (nAMD) previously treated with other anti-vascular endothelial growth factor (anti-VEGF) therapies after 12 months of follow-up. Methods: We performed a retrospective study of 30 eyes from 30 patients with nAMD who were switched to faricimab. The choroidal vascularity index (CVI), best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (CST), and the presence of subretinal fluid, intraretinal fluid, and wet macula were assessed at baseline and after 6 and 12 months. Results: CVI remained stable during follow-up (p > 0.05). BCVA improved significantly after 6 months (p = 0.041), but not at 12 months (p = 0.075). A significant reduction in CMT was observed (p < 0.05). Additionally, wet macula improved after 12 months (p < 0.05). Moreover, treatment intervals increased from 7.53 ± 2.39 to 12.47 ± 4.51 weeks. Conclusions: Switching to faricimab in patients with nAMD previously treated with other anti-VEGF therapies was associated with anatomical improvement, extended treatment intervals, and short-term visual gains, while choroidal vascular structure was maintained. Nonetheless, additional studies are warranted to more comprehensively evaluate the effectiveness of switching to faricimab, as well as the associated changes in choroidal vascular structure. Full article
Show Figures

Figure 1

Back to TopTop